Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance
DJ Tenney, KA Pokornowski, RE Rose, CJ Baldick, BJ Eggers, J Fang, JY Yang, D Xu, H Brett-Smith, N Spiegelmacher, A Schwendel, T Pichl, I Reeb, RJ Colonno · Zeitschrift für Gastroenterologie · 2008 · Heft 09
Bibliografische Angaben
Zusammenfassung
Aims: Entecavir (ETV) provides both potent viral suppression and a high genetic barrier to resistance, requiring ≥3 resistance substitutions. As a result, in nucleoside-naïve patients, ETV resistance (ETVr) was rare through 4 years. The genetic barrier in lamivudine(LVD)-refractory patients was reduced. Methods: All patients receiving continuous therapy in phase II/III trials were monitored for resistance through year 5. Detectable patient HBV DNA (≥300 copies/mL) was sequenced in each year. Cumulative probabilities of resistance were determined through year 5. Results: In years 1 through 5, respectively, 663, 2…
